Seegene Inc - Company Profile
Powered by 
All the data and insights you need on Seegene Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Seegene Inc Strategy Report
- Understand Seegene Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Seegene Inc (Seegene) is a medical device company that develops molecular diagnostic reagents. The company offering products includes Seeplex, anyplex and magicplex among others in the areas of Respiratory Infections, Gastrointestinal Tract Infections, Sexually Transmitted Infections, Human Papillomavirus Infections, Tuberculosis, Sepsis and Meningitis, among others. It develops ACP, DPO, READ, MuDT and TOCE technologies that enable to detect multiple pathogens in single reactions using Real-time PCR methods. Seegene’s IVD reagents are used in testing respiratory pathogens, gastrointestinal pathogens, sexually transmitted infections, human papillomavirus, tuberculosis and sepsis and meningitis pathogen, among others. The company serves commercial laboratories, DNA chip-based companies and molecular diagnostic companies. It operates in the US, Canada, South Korea, Brazil, Mexico, Italy, Middle East, and Germany. Seegene is headquartered in Seoul, South Korea.
Headquarters
South Korea
Address
Taewon Bldg., 91, Ogeum-Ro, Songpa-Gu, Seoul, 05548
Website
www.seegene.com
Telephone
82 2 22404000
No of Employees
215
Industry
Medical Equipment
Ticker Symbol & Exchange
096530 (KDQ)
Revenue (2022)
$661.2M
-37.7%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-66.1%
(2022 vs 2021)
Market Cap*
$976.2M
Net Profit Margin (2022)
XYZ
-45.5%
(2022 vs 2021)
* As of and is in US$
Seegene Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Assays: | Allplex |
| Allplex 2019-nCoV assay | Anyplex |
| Allplex Bacterial Vaginosis Assay | DPO |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | New Products/Services | In October, the company developed 100% recyclable packaging for its diagnostic kits. |
| 2023 | New Products/Services | In July, the company launched syndromic quantitative PCR assays and a fully automated molecular diagnostic testing system, STARlet AIOS. |
| 2023 | Contracts/Agreements | In June, the company entered into a partnership agreement with Springer Nature to expand its OneSystem Business. |
Competitor Comparison
| Key Parameters | Seegene Inc | Samil Pharmaceutical Co Ltd | Hyundai Bioland Co Ltd | Curexo Inc | Seoul Pharma Co Ltd |
|---|---|---|---|---|---|
| Headquarters | South Korea | South Korea | South Korea | South Korea | South Korea |
| City | Seoul | Seoul | Cheongju | Seoul | Cheongju |
| State/Province | Seoul | - | - | - | - |
| No. of Employees | 215 | 395 | 258 | 86 | 181 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jinsoo Choi | Chief Executive Officer; Director | Executive Board | - | 71 |
| Cheon Jong Yoon | Chief Executive Officer; Director | Executive Board | - | 66 |
| Changse Lee | Director | Non Executive Board | 2020 | 61 |
| Ahn Myung Wook | Director | Non Executive Board | 2023 | 63 |
| Hyeoncheol Jeong | Director | Non Executive Board | 2022 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2023 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward